Monte Rosa Therapeutics

IPO

Degrading proteins, making medicines

Public · Boston, United States · Founded 2018 · $127.5M raised

Employees
51–200
Founded
2018
Business Model
B2B
Total Funding
$127.5M
Last Round
$95.0M Series CMar 2021
Rounds
2
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing molecular glue degrader (MGD) medicines that reprogram ubiquitin ligases to eliminate disease-driving proteins previously considered undruggable. The company's proprietary platform integrates MGD chemistry, AI, structural biology, and proteomics to advance programs targeting cancer and other serious diseases.

Summary

Monte Rosa Therapeutics is a Biotech company based in Boston, United States, founded in 2018. It has raised $127.5M in total across 2 rounds, most recently a $95.0M Series C round in Mar 2021. Investors include Avoro Ventures, New Enterprise Associates and Versant Ventures.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

IPOJun 2021
$222.3M

Sign up to see all 3 events

Funding: Series B through Series C. Amounts, valuations, and investors where available.

Investors

Similar Companies

Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
OricIPO

San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...

South San Francisco, United States51–200Biotech, Healthcare
Private EquityTotal funding$647.0MFeb 2026
Neumora TherapeuticsIPO

Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...

Watertown, United States51–200Biotech, Drug Discovery
Series BTotal funding$612.0MOct 2022
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Monte Rosa Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/monte-rosa-therapeutics"><img src="https://indexed.vc/api/badge/company/monte-rosa-therapeutics" alt="Monte Rosa Therapeutics on Indexed.vc" width="260" height="76" /></a>